US Radiation Oncology Alternative Payment Model (RO-APM)


Moffitt Cancer Center; 2021 -- "Assessment of MRI-Linac Economics under the RO-APM" (Palm RF, J Clin Med. 2021 Oct 14;10(20):4706.). Paper Link

  • Comparison of technical fee reimbursement under Fee-For-Service (FFS) versus RO-APM reimbursement for MRI-Linac guided treatment. 200 patients, breast (31%), lung (13%), rectal (15%), pancreas/HPB (28%), prostate (13%)
  • Result: FFS revenue $10.9M vs RO-APM $2.4M (-78%). Lung -89%, pancreas -83%, breast -74%, CRC -65%, prostate -48%
  • Conclusion: Implementation of MRI-guided RT is susceptible under RO-APM